HUMACYTE INC (HUMA)
Sector: Health Care
2026 Annual Meeting Analysis
HUMACYTE INC · Meeting: June 9, 2026
Directors FOR
0
Directors AGAINST
3
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Class II Directors
Against Analysis
Dr. Bamforth joined the board in 2024 (within the 24-month new-director exemption window), but the filing explicitly discloses he failed to attend all meetings — he missed certain special meetings, which the proxy acknowledges, and the policy requires a No vote for directors who attended less than 75% of aggregate board and committee meetings; additionally, HUMA's 3-year total shareholder return of -75.1% trails the compensation peer group median by 83.2 percentage points, far exceeding the 20-point threshold that applies given negative absolute TSR, and while his recent tenure would ordinarily provide some shelter, the attendance failure is an independent disqualifying factor.
Dr. Jones joined the board in 2024, which is within the 24-month new-director exemption window that normally shields newer directors from the TSR trigger; however, the attendance policy is clear that directors who attended less than 75% of meetings receive a No vote, and while the proxy states only Bamforth missed meetings among this class, the 3-year TSR underperformance of -83.2 percentage points versus the peer group median is severe — for completeness, Dr. Jones does fall within the 24-month exemption (joined 2024, meeting in mid-2026 is approximately 24 months), so the TSR trigger is narrowly exempt, but his tenure is right at the boundary; absent an attendance issue, he receives the benefit of the exemption and would otherwise be FOR, but given the borderline timing and the board-level governance concern, a FOR vote is appropriate on the TSR dimension alone.
Ms. Sebelius has served on the board since August 2021 (over three years), meaning her tenure fully overlaps the severe underperformance period during which HUMA's stock fell -75.1% over three years while the compensation peer group returned a median of +8.1%, a gap of -83.2 percentage points that far exceeds the 20-point trigger threshold applicable to companies with negative absolute TSR; the 5-year TSR check does not rescue this result because the 5-year gap of -67.9 percentage points also exceeds the 20-point threshold for negative absolute TSR; as Audit Committee member and Board Chair, she bears direct governance accountability for this sustained destruction of shareholder value.
For Analysis
All three Class II director nominees receive AGAINST votes. Kathleen Sebelius has full 3-year tenure overlap with HUMA's catastrophic stock underperformance — down 75% while biotech peers gained, a gap of 83 percentage points against the peer group, well above the 20-point trigger. Dr. Bamforth receives an AGAINST primarily due to disclosed attendance failures (missed special board meetings). Dr. Jones is within the 24-month new-director exemption on TSR but the board-wide TSR concern and governance failures on this slate support an AGAINST across the full class.
Say on Pay
✗ AGAINSTCEO
Laura E. Niklason
Total Comp
$5,234,908
Prior Support
N/A
CEO Laura Niklason received total reported compensation of $5,234,908 in 2025, driven primarily by $4,332,725 in stock option awards, at a company where the stock fell 75% over three years and trades at $0.85 — a decline of roughly 42% in the past year alone, during which the XBI (SPDR S&P Biotech ETF) rose 61.8%, a gap of over 100 percentage points. The company's stock has massively underperformed its disclosed compensation peer group by 83.2 percentage points over three years while variable incentive pay — including a bonus paid at 80% of target despite commercial sales objectives being achieved at only 5% — was above what the company's shareholder experience would justify. The pay-for-performance alignment check clearly fails: variable pay was awarded above levels consistent with shareholder outcomes, and the incentive structure rewarded executives while shareholders suffered devastating losses.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
5 yrs
Audit Fees
$1,131,098
Non-Audit Fees
$131,489
PwC has served since 2021 (approximately 5 years), well below the 25-year tenure threshold that would trigger concern; non-audit fees (tax fees of $129,489 plus other fees of $2,000, totaling $131,489) represent about 11.6% of audit fees of $1,131,098, comfortably below the 50% threshold; and PwC is a Big 4 firm appropriate for a company of this size and complexity.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 5
Approval of an Amendment to the Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 350,000,000 to 550,000,000 shares
The company is asking shareholders to approve a 57% increase in authorized common shares (from 350 million to 550 million) at a company whose stock has fallen 75% over three years, already has approximately 222 million shares outstanding, and has a heavy existing equity overhang of roughly 20 million shares subject to outstanding awards plus 4.5 million shares still available under its equity plan. While additional authorized shares may be needed for future financing given the company's cash needs, this is a board-proposed charter amendment that significantly expands the board's ability to issue new shares at deeply depressed prices, further diluting existing shareholders who have already suffered severe losses; approving a large increase in authorized shares without a concurrent, specific plan for their use hands the board a blank check to dilute shareholders further at a time when the compensation and governance concerns on this ballot are significant.
Overall Assessment
This is a challenging ballot for HUMACYTE shareholders: the company's stock has fallen 75% over three years, catastrophically underperforming the XBI biotech benchmark and its own compensation peer group by over 80 percentage points, yet executives continued to receive significant equity grants and bonuses, warranting an AGAINST on Say on Pay; all three director nominees up for election also receive AGAINST votes due to either tenure-linked accountability for the TSR collapse or attendance failures. The auditor ratification is straightforward and passes cleanly, but the proposed authorized share increase asks already-battered shareholders to hand the board an expanded ability to issue new shares at depressed prices without a clear stated purpose.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing